SIO2022 Oral Abstract Presentations

Scientific Oral Abstract Presentations take place on Friday 25 March - Sunday 27 March 2022, from 5:15 pm - 6:15 pm PST each evening.

NEW IN 2022: SIO Debuts take place during the Scientific Oral Abstract Presentations on Saturday 5 February. SIO Debuts feature abstracts submitted and presented for the first time in a scientific meeting.

Friday 25 March

Scientific Oral Abstract Presentations | 5:15 pm - 6:15 pm PST

  • Primary Tumor Sidedness, RAS and BRAF Mutations and MSI Status as Prognostic Factors in Patients with Colorectal Liver Metastases: Results from the AmCORE, Madelon Dijkstra, Amsterdam University Medical Centers, VU Medical Center Amsterdam
  • A randomized, open-label, international, multicenter, phase 3 trial of radioembolization with chemotherapy for colorectal liver metastases: The EPOCH study, Robert Lewandowski, Northwestern University
  • Y90 Radiation Segmentectomy of HCC: A Comparative Study of Effectiveness, Safety and Dosimetry of Glass vs. Resin-based Microspheres, Alexander Villalobos, Emory University School of Medicine
  • Lymphatic Embolization vs. Sclerotherapy in management of Iatrogenic Lymphoceles after Oncological Surgery, Ahmed Aly, Memorial Sloan Kettering Cancer Center
  • Characterizing Combined Hepatocellular Cholangiocarcinoma in Patients Who Have Undergone Treatment With Locoregional Therapies, Anusha Naik, University of Pennsylvania
  • Percutaneous Microwave Ablation for Soft Tissue Retroperitoneal Tumors, Annika Rossebo, University of Wisconsin - Madison
  • Augmented Fluoroscopy Guided Transbronchial Pulmonary Microwave Ablation Obviates the Need for a Bronchoscope, Mario Ghosn, Memorial Sloan Kettering Cancer Center

Saturday 26 March

SIO Debuts Scientific Oral Abstract Presentations | 5:15 pm - 6:15 pm PST

  • Prospective study on the immunological effects of conventional transarterial chemoembolization in patients with hepatocellular carcinoma - An interim analysis, Robin Schmidt, Department of Radiology, Charité Virchow Klinikum
  • Virtual platform for assessing liver tumor ablation margin: Microwave ablation vs Intravascular Plasmonic Photothermal Ablation, Mir Hadi Razeghi Kondelaji, Medical College of Wisconsin
  • Improved outcomes of thermal ablation for colorectal liver metastases: a 10-year analysis from the prospective Amsterdam CORE registry (AmCORE), Robbert S. Puijk, Amsterdam University Medical Centers, VU Medical Center Amsterdam
  • Real-time PET Improves Tumor Detection and Ablation Margin Calculation when Used in Combination with CT-guided Ablation of Colorectal Liver Metastases, Mahdi Zirakchian Zadeh, Memorial Sloan Kettering
  • Hepatic and Renal Histotripsy in an Anticoagulated Swine Model, Scott Mauch, University of Wisconsin
  • Percutaneous Vesselplasty in Osteolytic Primary or Secondary Vertebral Lesions After the Radiofrequency Ablation: Safety and Efficacy, Matteo BelliniAzienda Ospedaliera Universitaria Senese

Sunday 27 March

Scientific Oral Abstract Presentations + Awards | 5:15 pm - 6:30 pm PST

  • 3D quantitative ablation margins for prediction of ablation site recurrence after stereotactic image-guided microwave ablation of colorectal liver metastasis, Simeon Ruiter, University Medical Center Groningen
  • In Situ Vaccination Approach to Treating HCC by Combining Percutaneous Cryoablation With a Plant Virus Nanoparticle Immunoadjuvant, Mansur Ghani, University of California, San Diego
  • Evaluation of LIRADS Treatment Response Criteria in Determining HCC Viability Post Locoregional Therapy in Transplant Patients, Ajay Makkena, Thomas Jefferson University
  • Antitumor Efficacy of Transarterial Bland Embolization with Concurrent Everolimus (EveroEmbo) in the Treatment of Hepatic Metastatic Neuroendocrine Tumors, Emad Chishti, University of Kentucky College of Medicine
  • Randomized Trial of Transarterial Chemoembolization With or Without Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma as Bridge to Transplant, Gregory Nadolski, University of Pennsylvania
  • The role of a navigational radiofrequency ablation device and concurrent vertebral augmentation for treatment of difficult-to-reach spinal metastases, Claudio Pusceddu, Oncological and Interventional Radiology Departement ARNAS